Header Logo

Connection

WAYNE GOODMAN to Adult

Back to Details
This is a "connection" page, showing publications WAYNE GOODMAN has written about Adult.
WAYNE GOODMAN
Connection Strength
1.506
Adult
  1. Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders. Am J Psychiatry. 2025 Mar 01; 182(3):285-296.
    View in: PubMed
    Score: 0.056
  2. Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal Stimulation Sites. Biol Psychiatry. 2024 Jul 15; 96(2):101-113.
    View in: PubMed
    Score: 0.052
  3. Impact of the COVID-19 pandemic on exposure and response prevention outcomes in adults and youth with obsessive-compulsive disorder. Psychiatry Res. 2021 01; 295:113597.
    View in: PubMed
    Score: 0.042
  4. Moderators and predictors of response to deep transcranial magnetic stimulation for obsessive-compulsive disorder. J Psychiatr Res. 2021 04; 136:508-514.
    View in: PubMed
    Score: 0.042
  5. Psychiatric Diagnoses and Medications for Hurricane Harvey Sheltered Evacuees. Community Ment Health J. 2019 10; 55(7):1099-1102.
    View in: PubMed
    Score: 0.037
  6. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019 01; 44(2):390-398.
    View in: PubMed
    Score: 0.036
  7. Meeting the Mental Health Needs of Hurricane Harvey Evacuees. Am J Psychiatry. 2018 Jan 01; 175(1):13-14.
    View in: PubMed
    Score: 0.034
  8. Altered olfactory processing and increased insula activity in patients with obsessive-compulsive disorder: An fMRI study. Psychiatry Res Neuroimaging. 2017 Apr 30; 262:15-24.
    View in: PubMed
    Score: 0.032
  9. Switching between internally and externally focused attention in obsessive-compulsive disorder: Abnormal visual cortex activation and connectivity. Psychiatry Res Neuroimaging. 2017 Jul 30; 265:87-97.
    View in: PubMed
    Score: 0.031
  10. Neural correlates of emotional response inhibition in obsessive-compulsive disorder: A preliminary study. Psychiatry Res. 2015 Nov 30; 234(2):259-64.
    View in: PubMed
    Score: 0.029
  11. The Persistence of Experience: Prior Attentional and Emotional State Affects Network Functioning in a Target Detection Task. Cereb Cortex. 2015 Sep; 25(9):3235-48.
    View in: PubMed
    Score: 0.027
  12. The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 2012 Feb; 53(2):187-94.
    View in: PubMed
    Score: 0.022
  13. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition. Psychol Assess. 2010 Jun; 22(2):223-32.
    View in: PubMed
    Score: 0.020
  14. Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord. 2010 Aug; 24(6):650-6.
    View in: PubMed
    Score: 0.020
  15. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist. J Clin Psychol. 2008 Dec; 64(12):1338-51.
    View in: PubMed
    Score: 0.018
  16. Insight in pediatric obsessive-compulsive disorder: associations with clinical presentation. Psychiatry Res. 2008 Aug 15; 160(2):212-20.
    View in: PubMed
    Score: 0.018
  17. Cognitive-behavioral therapy for obsessive-compulsive disorder: a non-randomized comparison of intensive and weekly approaches. J Anxiety Disord. 2008 Oct; 22(7):1146-58.
    View in: PubMed
    Score: 0.017
  18. Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder. Acta Psychiatr Scand. 2008 Jan; 117(1):67-75.
    View in: PubMed
    Score: 0.017
  19. Florida Obsessive-Compulsive Inventory: development, reliability, and validity. J Clin Psychol. 2007 Sep; 63(9):851-9.
    View in: PubMed
    Score: 0.017
  20. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
    View in: PubMed
    Score: 0.017
  21. Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming. J Neurol Neurosurg Psychiatry. 2007 Mar; 78(3):310-4.
    View in: PubMed
    Score: 0.016
  22. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):332-7.
    View in: PubMed
    Score: 0.016
  23. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety. 2006; 23(7):429-33.
    View in: PubMed
    Score: 0.015
  24. Hope and coping in family members of patients with obsessive-compulsive disorder. J Anxiety Disord. 2006; 20(5):614-29.
    View in: PubMed
    Score: 0.015
  25. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
    View in: PubMed
    Score: 0.015
  26. Psychometric properties of the Spanish Yale-Brown Obsessive-Compulsive Scale - Second Edition. Psychiatry Res. 2025 Jun; 348:116456.
    View in: PubMed
    Score: 0.014
  27. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
    View in: PubMed
    Score: 0.014
  28. Yale-Brown Obsessive Compulsive Scale: the dimensional structure revisited. Depress Anxiety. 2005; 22(1):28-35.
    View in: PubMed
    Score: 0.014
  29. Aperiodic spectral slope tracks the effects of brain state on saliency responses in the human auditory cortex. Sci Rep. 2024 12 28; 14(1):30751.
    View in: PubMed
    Score: 0.014
  30. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.014
  31. Psychometric Properties of the Yale-Brown Obsessive Compulsive Scale-II Self-Report. J Psychiatr Pract. 2024 Nov 01; 30(6):421-427.
    View in: PubMed
    Score: 0.014
  32. Parent perceptions of various treatment approaches for PANS and PANDAS. J Affect Disord. 2025 Jan 15; 369:1215-1222.
    View in: PubMed
    Score: 0.014
  33. Misconceptions Among Mental Health Treatment Providers About OCD and PTSD. Behav Ther. 2025 05; 56(3):470-486.
    View in: PubMed
    Score: 0.014
  34. What's in a "smile?" Intra-operative observations of contralateral smiles induced by deep brain stimulation. Neurocase. 2004 Aug; 10(4):271-9.
    View in: PubMed
    Score: 0.014
  35. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.014
  36. Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med. 2024 Oct; 30(10):3004-3014.
    View in: PubMed
    Score: 0.014
  37. A Low-Intensity Transcranial Focused Ultrasound Parameter Exploration Study of the Ventral Capsule/Ventral Striatum. Neuromodulation. 2025 Jan; 28(1):146-154.
    View in: PubMed
    Score: 0.013
  38. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 01; 55(5):553-5.
    View in: PubMed
    Score: 0.013
  39. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry. 2003 Oct 01; 54(7):751-6.
    View in: PubMed
    Score: 0.013
  40. Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review. Pharmacoeconomics. 2023 05; 41(5):499-527.
    View in: PubMed
    Score: 0.012
  41. Tractography-Based Modeling Explains Treatment Outcomes in Patients Undergoing Deep Brain Stimulation for Obsessive-Compulsive Disorder. Biol Psychiatry. 2024 Jul 15; 96(2):95-100.
    View in: PubMed
    Score: 0.012
  42. Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder. Psychiatr Clin North Am. 2023 03; 46(1):167-180.
    View in: PubMed
    Score: 0.012
  43. Intraoperative valence testing to adjudicate between ventral capsule/ventral striatum and bed nucleus of the stria terminalis target selection in deep brain stimulation for obsessive-compulsive disorder. J Neurosurg. 2023 08 01; 139(2):442-450.
    View in: PubMed
    Score: 0.012
  44. Perceptions of various treatment approaches for adults and children with misophonia. J Affect Disord. 2022 11 01; 316:76-82.
    View in: PubMed
    Score: 0.012
  45. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002 Jun; 5(2):141-5.
    View in: PubMed
    Score: 0.012
  46. Provider perceptions of telehealth and in-person exposure and response prevention for obsessive-compulsive disorder. Psychiatry Res. 2022 07; 313:114610.
    View in: PubMed
    Score: 0.012
  47. Primary Outcomes for Adults Receiving the Unified Protocol after Hurricane Harvey in an Integrated Healthcare Setting. Community Ment Health J. 2022 11; 58(8):1522-1534.
    View in: PubMed
    Score: 0.012
  48. Family Accommodation of Symptoms in Adults With Obsessive-Compulsive Disorder: Factor Structure and Usefulness of the Family Accommodation Scale for OCD-Patient Version. J Psychiatr Pract. 2022 01 06; 28(1):36-47.
    View in: PubMed
    Score: 0.011
  49. Anxiety in Angelman Syndrome. Am J Intellect Dev Disabil. 2022 01 01; 127(1):1-10.
    View in: PubMed
    Score: 0.011
  50. Cost-effectiveness analysis of deep transcranial magnetic stimulation relative to evidence-based strategies for treatment-refractory obsessive-compulsive disorder. J Psychiatr Res. 2022 02; 146:50-54.
    View in: PubMed
    Score: 0.011
  51. Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder. Nat Med. 2021 12; 27(12):2154-2164.
    View in: PubMed
    Score: 0.011
  52. Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. J Neuroimmunol. 2001 Nov 01; 120(1-2):146-51.
    View in: PubMed
    Score: 0.011
  53. Obsessive compulsive disorder: is there an association with childhood streptococcal infections and altered immune function? Semin Clin Neuropsychiatry. 2001 Oct; 6(4):266-76.
    View in: PubMed
    Score: 0.011
  54. Perceptions of Deep Brain Stimulation for Adolescents with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2021 03; 31(2):109-117.
    View in: PubMed
    Score: 0.011
  55. Family accommodation in Chinese individuals with obsessive-compulsive disorder. Psych J. 2021 Apr; 10(2):295-304.
    View in: PubMed
    Score: 0.011
  56. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.010
  57. Parent-led Behavioral Intervention for a Treatment-refusing Adult With Obsessive-Compulsive Disorder With Poor Insight and Extreme Family Accommodation. J Psychiatr Pract. 2020 03; 26(2):149-152.
    View in: PubMed
    Score: 0.010
  58. Serious negative consequences associated with exposure and response prevention for obsessive-compulsive disorder: A survey of therapist attitudes and experiences. Depress Anxiety. 2020 05; 37(5):418-428.
    View in: PubMed
    Score: 0.010
  59. Stability of subclinical obsessive compulsive disorder in college students. Depress Anxiety. 2000; 11(4):180-2.
    View in: PubMed
    Score: 0.010
  60. Development and psychometric evaluation of the Mandarin Chinese version of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Braz J Psychiatry. 2019 Nov-Dec; 41(6):494-498.
    View in: PubMed
    Score: 0.010
  61. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
    View in: PubMed
    Score: 0.010
  62. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry. 1999 Jun 01; 45(11):1440-6.
    View in: PubMed
    Score: 0.009
  63. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938.
    View in: PubMed
    Score: 0.009
  64. Chinese Therapists' Beliefs About Exposure Therapy for Anxiety and Obsessive-Compulsive Disorders. J Psychiatr Pract. 2019 05; 25(3):179-185.
    View in: PubMed
    Score: 0.009
  65. Incidence and clinical correlates of anger attacks in Chinese patients with obsessive-compulsive disorder. J Zhejiang Univ Sci B. 2019 Apr.; 20(4):363-370.
    View in: PubMed
    Score: 0.009
  66. Clinicians' perspectives of interfering behaviors in the treatment of anxiety and obsessive-compulsive disorders in adults and children. Cogn Behav Ther. 2020 01; 49(1):81-96.
    View in: PubMed
    Score: 0.009
  67. Functional neural mechanisms of sensory phenomena in obsessive-compulsive disorder. J Psychiatr Res. 2019 02; 109:68-75.
    View in: PubMed
    Score: 0.009
  68. Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining. BMC Med Inform Decis Mak. 2018 09 14; 18(Suppl 3):79.
    View in: PubMed
    Score: 0.009
  69. Habenular connectivity may predict treatment response in depressed psychiatric inpatients. J Affect Disord. 2019 01 01; 242:211-219.
    View in: PubMed
    Score: 0.009
  70. Politically-focused intrusive thoughts and associated ritualistic behaviors in a community sample. J Anxiety Disord. 2018 05; 56:35-42.
    View in: PubMed
    Score: 0.009
  71. Impact of the 2016 US presidential election on OCD symptom presentation: A case illustration. J Clin Psychol. 2018 05; 74(5):750-754.
    View in: PubMed
    Score: 0.009
  72. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: A meta-analysis of functional imaging studies. Eur Psychiatry. 2017 10; 46:25-32.
    View in: PubMed
    Score: 0.008
  73. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997; 33(1):17-22.
    View in: PubMed
    Score: 0.008
  74. Recent developments in neurobiology of obsessive-compulsive disorder. J Clin Psychiatry. 1996 Oct; 57(10):492-503.
    View in: PubMed
    Score: 0.008
  75. Resting-state functional connectivity of the human habenula in healthy individuals: Associations with subclinical depression. Hum Brain Mapp. 2016 07; 37(7):2369-84.
    View in: PubMed
    Score: 0.008
  76. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996 Mar; 11(1):21-9.
    View in: PubMed
    Score: 0.008
  77. Human habenula segmentation using myelin content. Neuroimage. 2016 Apr 15; 130:145-156.
    View in: PubMed
    Score: 0.008
  78. Subclinical obsessive-compulsive disorder in college students. Depress Anxiety. 1996-1997; 4(5):233-6.
    View in: PubMed
    Score: 0.007
  79. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec; 45(16):3571-80.
    View in: PubMed
    Score: 0.007
  80. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 01; 38(3):138-49.
    View in: PubMed
    Score: 0.007
  81. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015; 10(7):e0133591.
    View in: PubMed
    Score: 0.007
  82. Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical sample. J Neuropsychiatry Clin Neurosci. 2014; 26(1):81-6.
    View in: PubMed
    Score: 0.007
  83. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
    View in: PubMed
    Score: 0.006
  84. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013 Aug; 30(8):716-22.
    View in: PubMed
    Score: 0.006
  85. The relationship between insight and control in obsessive-compulsive disorder: implications for the insanity defense. Bull Am Acad Psychiatry Law. 1993; 21(2):245-52.
    View in: PubMed
    Score: 0.006
  86. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013 Jan; 70(1):85-94.
    View in: PubMed
    Score: 0.006
  87. Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am. 1992 Dec; 15(4):861-9.
    View in: PubMed
    Score: 0.006
  88. Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues. Brain Stimul. 2012 Oct; 5(4):599-604.
    View in: PubMed
    Score: 0.006
  89. Cerebral laterality, perception of emotion, and treatment response in obsessive-compulsive disorder. Biol Psychiatry. 1991 May 01; 29(9):900-8.
    View in: PubMed
    Score: 0.005
  90. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990 Dec; 20(4):537-43.
    View in: PubMed
    Score: 0.005
  91. Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res. 2011 Feb 28; 185(3):394-401.
    View in: PubMed
    Score: 0.005
  92. A case of mania following deep brain stimulation for obsessive compulsive disorder. Stereotact Funct Neurosurg. 2010; 88(5):322-8.
    View in: PubMed
    Score: 0.005
  93. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry. 2010 Aug; 71(8):e1-e21.
    View in: PubMed
    Score: 0.005
  94. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry. 2010 Aug; 71(8):1040-6.
    View in: PubMed
    Score: 0.005
  95. Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 2010 Aug 15; 178(3):467-74.
    View in: PubMed
    Score: 0.005
  96. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun; 47(6):577-85.
    View in: PubMed
    Score: 0.005
  97. Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage. 2011 Jan; 54 Suppl 1:S247-55.
    View in: PubMed
    Score: 0.005
  98. Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder. Neurocase. 2010 Aug; 16(4):321-30.
    View in: PubMed
    Score: 0.005
  99. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989 Nov; 46(11):1012-6.
    View in: PubMed
    Score: 0.005
  100. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov; 46(11):1006-11.
    View in: PubMed
    Score: 0.005
  101. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010 Feb; 121(1-2):175-9.
    View in: PubMed
    Score: 0.005
  102. Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth. Child Psychiatry Hum Dev. 2009 Sep; 40(3):467-83.
    View in: PubMed
    Score: 0.005
  103. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan; 46(1):36-44.
    View in: PubMed
    Score: 0.005
  104. Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2008 Jul; 47(7):763-772.
    View in: PubMed
    Score: 0.004
  105. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010 Jan; 15(1):64-79.
    View in: PubMed
    Score: 0.004
  106. Associations between miscellaneous symptoms and symptom dimensions in adults with obsessive-compulsive disorder. Anxiety Stress Coping. 2008 Apr; 21(2):199-212.
    View in: PubMed
    Score: 0.004
  107. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.004
  108. Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist. J Anxiety Disord. 2008 Dec; 22(8):1369-76.
    View in: PubMed
    Score: 0.004
  109. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov; 31(11):2384-93.
    View in: PubMed
    Score: 0.004
  110. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry. 1986 Jul; 143(7):900-3.
    View in: PubMed
    Score: 0.004
  111. Long-term habituation of the smile response with deep brain stimulation. Neurocase. 2006 Jun; 12(3):191-6.
    View in: PubMed
    Score: 0.004
  112. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry. 2004 Jun; 65(6):742-9.
    View in: PubMed
    Score: 0.003
  113. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
    View in: PubMed
    Score: 0.003
  114. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Sep; 15(3):159-75.
    View in: PubMed
    Score: 0.003
  115. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry. 2002 Feb; 159(2):263-8.
    View in: PubMed
    Score: 0.003
  116. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001 Feb; 21(1):46-52.
    View in: PubMed
    Score: 0.003
  117. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999 May; 60(5):346-51; quiz 352.
    View in: PubMed
    Score: 0.002
  118. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res. 1999 Mar 22; 85(3):225-40.
    View in: PubMed
    Score: 0.002
  119. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology. 1999 Jan; 24(1):1-24.
    View in: PubMed
    Score: 0.002
  120. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997 Sep; 154(9):1293-5.
    View in: PubMed
    Score: 0.002
  121. Symptoms of obsessive-compulsive disorder. Am J Psychiatry. 1997 Jul; 154(7):911-7.
    View in: PubMed
    Score: 0.002
  122. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry. 1997 May 01; 41(9):949-54.
    View in: PubMed
    Score: 0.002
  123. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry. 1997 Mar; 154(3):402-7.
    View in: PubMed
    Score: 0.002
  124. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 01; 41(1):117-21.
    View in: PubMed
    Score: 0.002
  125. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep; 153(9):1232-3.
    View in: PubMed
    Score: 0.002
  126. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 01; 39(9):776-83.
    View in: PubMed
    Score: 0.002
  127. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995 Dec; 152(12):1812-4.
    View in: PubMed
    Score: 0.002
  128. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry. 1995 Jul 15; 38(2):74-85.
    View in: PubMed
    Score: 0.002
  129. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995 May; 152(5):772-7.
    View in: PubMed
    Score: 0.002
  130. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995 Mar; 152(3):441-3.
    View in: PubMed
    Score: 0.002
  131. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995 Feb; 12(1):73-86.
    View in: PubMed
    Score: 0.002
  132. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):76-84.
    View in: PubMed
    Score: 0.002
  133. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):90-6.
    View in: PubMed
    Score: 0.002
  134. Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994 Dec 01; 36(11):775-7.
    View in: PubMed
    Score: 0.002
  135. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry. 1994 Oct; 51(10):782-92.
    View in: PubMed
    Score: 0.002
  136. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
    View in: PubMed
    Score: 0.002
  137. "Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry. 1994 May; 151(5):675-80.
    View in: PubMed
    Score: 0.002
  138. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry. 1994 Apr; 164(4):469-73.
    View in: PubMed
    Score: 0.002
  139. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
    View in: PubMed
    Score: 0.002
  140. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
    View in: PubMed
    Score: 0.002
  141. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry. 1994 Mar; 55 Suppl:24-31.
    View in: PubMed
    Score: 0.002
  142. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994 Feb; 151(2):289.
    View in: PubMed
    Score: 0.002
  143. Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety. 1994-1995; 1(5):208-15.
    View in: PubMed
    Score: 0.002
  144. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry. 1993 Dec; 44(12):1150-4.
    View in: PubMed
    Score: 0.002
  145. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993 Oct; 13(5):354-8.
    View in: PubMed
    Score: 0.002
  146. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993 Aug; 48(2):119-33.
    View in: PubMed
    Score: 0.002
  147. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993 Apr; 150(4):647-9.
    View in: PubMed
    Score: 0.002
  148. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry. 1993 Apr 01; 33(7):547-50.
    View in: PubMed
    Score: 0.002
  149. Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Am J Psychiatry. 1992 Oct; 149(10):1406-7.
    View in: PubMed
    Score: 0.001
  150. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992 Jul; 31(4):746-50.
    View in: PubMed
    Score: 0.001
  151. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991 Jun; 11(3):175-84.
    View in: PubMed
    Score: 0.001
  152. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry. 1990 Nov; 157:762-5.
    View in: PubMed
    Score: 0.001
  153. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990 May; 147(5):652-4.
    View in: PubMed
    Score: 0.001
  154. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull. 1990; 26(1):54-9.
    View in: PubMed
    Score: 0.001
  155. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26(3):279-84.
    View in: PubMed
    Score: 0.001
  156. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988 Feb; 45(2):177-85.
    View in: PubMed
    Score: 0.001
  157. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry. 1988 Jan; 45(1):43-52.
    View in: PubMed
    Score: 0.001
  158. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987 Aug; 144(8):1030-6.
    View in: PubMed
    Score: 0.001
  159. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987 Aug; 144(8):1059-61.
    View in: PubMed
    Score: 0.001
  160. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl). 1987; 93(3):308-13.
    View in: PubMed
    Score: 0.001
  161. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl). 1987; 92(1):14-24.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.